Pharis Mohideen
DBV Technologies (France)(FR)
Publications by Year
Research Areas
Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Diabetes, Cardiovascular Risks, and Lipoproteins, Diabetes Management and Research, Menopause: Health Impacts and Treatments
Most-Cited Works
- → Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.(2000)348 cited
- → Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial(2010)202 cited
- → Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial(2017)195 cited
- → Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study(2012)194 cited
- → Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial(2008)167 cited
- → Troglitazone but not Metformin Restores Insulin-Stimulated Phosphoinositide 3-Kinase Activity and Increases p110β Protein Levels in Skeletal Muscle of Type 2 Diabetic Subjects(2002)128 cited
- → Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy(2006)114 cited
- → Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action(2018)93 cited
- → Metformin‐glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy(2005)83 cited
- → A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma(2020)55 cited